RenBio (United States)
RenBio is a company focused on advancing DNA therapeutic technologies to deliver next-generation medicines.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
RenBio is a company that aims to advance first-in-class and best-in-class DNA therapeutic technologies to humans. Its mission is to make antibody therapeutics available to everyone, and its vision is to modernize and transform the antibody and therapeutic protein fields. The company develops the MYO Technology, a platform for delivering therapeutic-encoding 'bioblueprints' via modified intramuscular injection.
History
RenBio was founded on the principle that the remarkable medical benefits of antibody therapeutics should be available to everyone. The company's mission is to advance first-in-class and best-in-class DNA therapeutic technologies to humans. Its vision is to modernize and transform the antibody and therapeutic protein fields to enable long-lasting delivery and significantly reduce the impact of diseases worldwide. RenBio's MYO Technology is a platform technology that delivers therapeutic-encoding 'bioblueprints' via modified intramuscular injection, which are then decoded by muscle cells to produce disease-fighting therapeutics in the patient's own body.
Products and positioning
MYO Technology
Recent events
RenBio licenses Columbia University's RB-100 antibody[3]
Reported:
RenBio signed a license agreement with Columbia University granting RenBio exclusive worldwide development and commercialization rights to the RB-100 bispecific antibody for COVID-19.
RenBio completes $24 million Series A financing[3]
Reported:
RenBio announced that it completed a $24 million Series A financing led by Taiwan-based Ruentex Group.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/renbio-united-states · Editorial policy · How profiles are compiled